Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging

Angiogenesis

Volumn 14, Issue 4, 2011, Pages 491-501

  Seshadri, Mukund ^a   Sacadura, Nuno T ^b   Coulthard, Tonya ^b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Sonics Inc   (Canada)

^c Aspect Imaging   (Canada)

Author keywords

Angiogenesis; MRI; SCCHN; US; VDAs

Indexed keywords

VADIMEZAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VOLUME; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN VIVO STUDY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRASOUND SCANNER;

ANIMALS; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; FEMALE; GADOLINIUM; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; XANTHONES;

MUS;

EID: 84855204530     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9233-1     Document Type: Article

References (46)

1. L Davies HG Welch 2006 Epidemiology of head and neck cancer in the United States Otolaryngol Head Neck Surg 135 451 457 16949981 10.1016/j.otohns.2006. 01.029 (Pubitemid 44292959)
2. LL Gleich PW Biddinger ZP Pavelic JL Gluckman 1996 Tumor angiogenesis in T1 oral cavity squamous cell carcinoma: role in predicting tumor aggressiveness Head Neck 18 343 346 8780945 10.1002/(SICI)1097-0347(199607/08)18:4<343::AID- HED5>3.0.CO;2-Y 1:STN:280:DyaK28znsVOiug%3D%3D (Pubitemid 26177708)
3. R Hasina ME Whipple LE Martin WP Kuo L Ohno-Machado MW Lingen 2008 Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications Lab Invest 88 342 353 18283272 10.1038/labinvest. 2008.6 1:CAS:528:DC%2BD1cXjs1aksr0%3D (Pubitemid 351432778)
4. FC Galmarini CM Galmarini MI Sarchi J Abulafia D Galmirini 2000 Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer Microcirculation 7 405 410 11142337 1:STN:280:DC%2BD3M7ksFKnsA%3D%3D
5. JH Kaanders KI Wijffels HA Marres AS Ljungkvist LA Pop FJ van den Hoogen PC de Wilde J Bussink JA Raleigh AJ van der Kogel 2002 Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 7066 7074 12460928 1:CAS:528:DC%2BD38XpsVahtro%3D (Pubitemid 35424102)
6. A Bozec A Sudaka JL Fischel MC Brunstein MC Etienne-Grimaldi G Milano 2008 Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model Br J Cancer 99 93 99 18577994 10.1038/sj.bjc.6604429 1:CAS:528:DC%2BD1cXnvFerurw%3D (Pubitemid 351920227)
7. K Fujita D Sano M Kimura Y Yamashita M Kawakami Y Ishiguro G Nishimura H Matsuda M Tsukuda 2007 Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma Oncol Rep 18 47 51 17549344 1:CAS:528:DC%2BD2sXot1Kmu70%3D
8. J Bernier 2008 A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update Curr Opin Oncol 20 249 255 18391622 10.1097/CCO.0b013e3282faa0b1 (Pubitemid 351507543)
9. JP Machiels S Henry S Zanetta MC Kaminsky N Michoux D Rommel S Schmitz E Bompas AF Dillies S Faivre A Moxhon T Duprez J Guigay 2010 Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 J Clin Oncol 28 21 28 19917865 10.1200/JCO.2009.23.8584 1:CAS:528:DC%2BC3cXhtF2ku7o%3D
10. GM Tozer C Kanthou BC Baguley 2005 Disrupting tumour blood vessels Nat Rev Cancer 5 423 435 15928673 10.1038/nrc1628 1:CAS:528:DC%2BD2MXks1Gmsr0%3D (Pubitemid 40791485)
11. JP O'Connor A Jackson GJ Parker GC Jayson 2007 DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 189 195 17211479 10.1038/sj.bjc.6603515 (Pubitemid 46160619)
12. N Hylton 2006 Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker J Clin Oncol 24 3293 3298 16829653 10.1200/JCO.2006.06.8080 1:CAS:528:DC%2BD28Xot1yhsrw%3D (Pubitemid 46622069)
13. Padhani AR, Choyke PL (2006) New techniques in oncologic imaging. Taylor and Francis, New York, pp 257-269
14. DM Koh DJ Collins 2007 Diffusion-weighted MRI in the body: applications and challenges in oncology AJR Am J Roentgenol 188 1622 1635 17515386 10.2214/AJR.06.1403 (Pubitemid 46866868)
15. M Seshadri M Merzianu H Tang NR Rigual M Sullivan TR Loree SR Popat EA Repasky BL Hylander 2009 Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts Cancer Biol Ther 8 2275 2283 19829072
16. G Korpanty JG Carbon PA Grayburn JB Fleming RA Brekken 2007 Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature Clin Cancer Res 13 323 330 17200371 10.1158/1078-0432.CCR-06-1313 1:CAS:528:DC%2BD2sXotlag (Pubitemid 46121886)
17. JC Sullivan B Wang EI Boesen G D'Angelo JS Pollock DM Pollock 2009 Novel use of ultrasound to examine regional blood flow in the mouse kidney Am J Physiol Renal Physiol 297 F228 F235 19420115 10.1152/ajprenal.00016.2009 1:CAS:528:DC%2BD1MXovVKhsb8%3D
18. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10647931 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D (Pubitemid 30046295)
19. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 273 286 17396134 10.1038/nrd2115 1:CAS:528: DC%2BD2sXjs1SisL4%3D Review (Pubitemid 46505878)
20. Y Yanagi J Asaumi T Unetsubo M Ashida T Takenobu M Hisatomi H Matsuzaki H Konouchi N Katase H Nagatsuka 2010 Usefulness of MRI and dynamic contrast-enhanced MRI for differential diagnosis of simple bone cysts from true cysts in the jaw Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110 364 369 20727497 10.1016/j.tripleo.2010.05.001
21. T Unetsubo H Konouchi Y Yanagi J Murakami M Fujii H Matsuzaki M Hisatomi H Nagatsuka J Asaumi 2009 Dynamic contrast-enhanced magnetic resonance imaging for estimating tumor proliferation and microvessel density of oral squamous cell carcinomas Oral Oncol 45 621 626 19027349 10.1016/j.oraloncology.2008.09.003
22. K Newbold I Castellano E Charles-Edwards D Mears A Sohaib M Leach P Rhys-Evans P Clarke C Fisher K Harrington C Nutting 2009 An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer Int J Radiat Oncol Biol Phys 74 29 37 19036529 10.1016/j.ijrobp.2008.07.039
23. C Hayes AR Padhani MO Leach 2002 Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging NMR Biomed 15 154 163 11870911 10.1002/nbm.756 (Pubitemid 34213405)
24. S Kim H Quon LA Loevner MA Rosen L Dougherty AM Kilger JD Glickson H Poptani 2007 Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck J Magn Reson Imaging 26 1607 1617 17968962 10.1002/jmri.21207 (Pubitemid 350301150)
25. EM Van Cann M Rijpkema A Heerschap A van der Bilt R Koole PJ Stoelinga 2008 Quantitative dynamic contrast-enhanced MRI for the assessment of mandibular invasion by squamous cell carcinoma Oral Oncol 44 1147 1154 18485797 10.1016/j.oraloncology.2008.02.009
26. Y Cao A Popovtzer D Li DB Chepeha JS Moyer ME Prince F Worden T Teknos C Bradford SK Mukherji A Eisbruch 2008 Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study Int J Radiat Oncol Biol Phys 72 1287 1290 19028268 10.1016/j.ijrobp.2008.08.024
27. Farace P, Merigo F, Fiorini S, Nicolato E, Tambalo S, Daducci A, Degrassi A, Sbarbati A, Rubello D, Marzola P (2011) DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content. Eur J Radiol 78(1):52-59
28. AA Forastiere H Goepfert M Maor TF Pajak R Weber W Morrison B Glisson A Trotti JA Ridge C Chao G Peters DJ Lee A Leaf J Ensley J Cooper 2003 Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 2091 2098 14645636 10.1056/NEJMoa031317 1:CAS:528:DC%2BD3sXptlKiu7s%3D (Pubitemid 37464533)
29. DW Siemann AM Rojiani 2005 The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors Int J Radiat Oncol Biol Phys 62 846 853 15936569 10.1016/j.ijrobp.2005. 02.048 1:CAS:528:DC%2BD2MXltVOnsbw%3D (Pubitemid 40779778)
30. M Seshadri K Toth 2009 Acute vascular disruption by 5,6- dimethylxanthenone-4-acetic acid in an orthotopic model of human head and neck cancer Transl Oncol 2 121 127 19701496
31. SC Yeung M She H Yang J Pan L Sun D Chaplin 2007 Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model J Clin Endocrinol Metab 92 2902 2909 17550961 10.1210/jc.2007-0027 1:CAS:528:DC%2BD2sXptl2hsrY%3D (Pubitemid 47236348)
32. MJ McKeage BC Baguley 2010 Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer Cancer 116 1859 1871 20166210 10.1002/cncr.24975 1:CAS:528:DC%2BC3cXlvVGlsbk%3D Review
33. LR Kelland 2005 Targeting established tumor vasculature: a novel approach to cancer treatment Curr Cancer Ther Rev 1 1 9 10.2174/1573394052952456
34. LD McPhail JR Griffiths SP Robinson 2007 Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging Int J Radiat Oncol Biol Phys 69 1238 1245 17967313 10.1016/j.ijrobp. 2007.08.025 1:CAS:528:DC%2BD2sXht1aktbzF (Pubitemid 47625879)
35. L-M Ching S Zwain BC Baguley 2004 Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice Br J Cancer 90 906 910 14970872 10.1038/sj.bjc.6601606 1:CAS:528:DC%2BD2cXht12iurg%3D (Pubitemid 38406605)
36. MJ McKeage P Fong M Jeffery BC Baguley P Kestell M Ravic MB Jameson 2006 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent Clin Cancer Res 12 1776 1784 16551862 10.1158/1078-0432.CCR-05-1939 1:CAS:528:DC%2BD28Xis1CjsLw%3D
37. SM Galbraith GJ Rustin MA Lodge NJ Taylor JJ Stirling M Jameson P Thompson D Hough L Gumbrell AR Padhani 2002 Effects of 5,6-dimethylxanthenone-4- acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol 20 3826 3840 12228202 10.1200/JCO.2002.09.144 1:CAS:528:DC%2BD38XntVyns7g%3D
38. SM Galbraith RJ Maxwell MA Lodge GM Tozer J Wilson NJ Taylor JJ Stirling L Sena AR Padhani GJ Rustin 2003 Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 2831 2842 12807936 10.1200/JCO.2003.05.187 1:CAS:528:DC%2BD2cXpsVKjsb8%3D (Pubitemid 46621830)
39. M Zweifel AR Padhani 2010 Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 37 S164 S182 20461374 10.1007/s00259-010-1451-z
40. L Bentzen P Vestergaard-Poulsen T Nielsen J Overgaard A Bjørnerud K Briley-Saebø MR Horsman L Ostergaard 2005 Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor Int J Radiat Oncol Biol Phys 61 1208 1215 15752903 10.1016/j.ijrobp.2004.12.020 1:CAS:528: DC%2BD2MXhvFykur8%3D (Pubitemid 40340917)
41. M Seshadri DA Bellnier RT Cheney 2008 Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors Int J Radiat Oncol Biol Phys 72 1198 1207 18954713 10.1016/j.ijrobp.2008.07.043 1:CAS:528:DC%2BD1cXht12gur7P
42. M Goyen K Shamsi SO Schoenberg 2006 Vasovist-enhanced MR angiography Eur Radiol 16 B9 B14 16802438 10.1007/s00330-005-0001-8 (Pubitemid 44149381)
43. K Turetschek E Floyd T Helbich TP Roberts DM Shames MF Wendland WO Carter RC Brasch 2001 MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology J Magn Reson Imaging 14 237 242 11536400 10.1002/jmri.1179 1:STN:280:DC%2BD3MvptFygsg%3D%3D (Pubitemid 32801057)
44. JP O'Connor RA Carano AR Clamp J Ross CC Ho A Jackson GJ Parker CJ Rose FV Peale M Friesenhahn CL Mitchell Y Watson C Roberts L Hope S Cheung HB Reslan MA Go GJ Pacheco X Wu TC Cao S Ross GA Buonaccorsi K Davies J Hasan P Thornton O del Puerto N Ferrara N van Bruggen GC Jayson 2009 Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 6674 6682 19861458 10.1158/1078-0432.CCR-09- 0731
45. DE Goertz JL Yu RS Kerbel PN Burns FS Foster 2002 High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow Cancer Res 62 6371 6375 12438217 1:CAS:528:DC%2BD38XovFOltbg%3D (Pubitemid 35364088)
46. S Masunaga H Nagasawa K Nagata M Suzuki Y Uto H Hori Y Kinashi K Ono 2007 Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells J Cancer Res Clin Oncol 133 47 55 16924543 10.1007/s00432-006-0145-1 1:CAS:528:DC%2BD28Xht1elsbjN (Pubitemid 44832779)